Insights

Strategic AI platform BenevolentAI has evolved from internal drug discovery AI to a market-facing strategic decision intelligence platform (Qor) for biotech leaders, signaling a potential upsell opportunity to license or deploy the platform across partner organizations seeking scalable biomedical insights.

Leadership shifts Recent leadership changes, including executive chairman and CFO appointments, indicate a focus on strategic realignment and financial discipline, presenting an opening for targeted outreach around enterprise-grade partnerships, licensing deals, or consulting services aligned with new strategic priorities.

Geographic consolidation The 2024 closure of the US office and focus on Cambridge and London operations suggest opportunities to engage with European biotech and life sciences clusters, offering localized services, support, and co-development collaborations that leverage existing regional presence.

Scale and sustainability With a modest headcount and mid-range revenue, BenevolentAI presents a prospect for cost-effective AI-enabled discovery services, SI partnerships, or managed cloud and data integration solutions to augment their AI infrastructure and accelerate workflow adoption.

Biomedical impact proof Past success such as the fast identification of baricitinib for Covid-19 demonstrates value; use cases and case studies around rapid hypothesis generation, data fusion, and explainable AI can be leveraged to engage buyers in pharma and biotech seeking proven ROI and risk reduction.

Similar companies to BenevolentAI

BenevolentAI Tech Stack

BenevolentAI uses 8 technology products and services including Grafana, Power BI, Apache Airflow, and more. Explore BenevolentAI's tech stack below.

Media & News

BenevolentAI's Email Address Formats

BenevolentAI uses at least 7 email formats:
BenevolentAI Email FormatsExamplePercentage
First.Last@benevolent.comJohn.Doe@benevolent.com
77%
First@benevolent.comJohn@benevolent.com
19%
FirstLast@benevolent.comJohnDoe@benevolent.com
4%
First.Last@benevolent.aiJohn.Doe@benevolent.ai
96%
First.Middle@benevolent.aiJohn.Michael@benevolent.ai
2%
First.Middle.Last@benevolent.aiJohn.Michael.Doe@benevolent.ai
1%
First@benevolent.aiJohn@benevolent.ai
1%

Frequently Asked Questions

What is BenevolentAI's stock symbol?

Minus sign iconPlus sign icon
BenevolentAI is a publicly traded company; the company's stock symbol is BAI.AS.

What is BenevolentAI's official website and social media links?

Minus sign iconPlus sign icon
BenevolentAI's official website is benevolent.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does BenevolentAI generate?

Minus sign iconPlus sign icon
As of October 2026, BenevolentAI's annual revenue is estimated to be $10M - $25M.

What is BenevolentAI's NAICS code?

Minus sign iconPlus sign icon
BenevolentAI's NAICS code is 5112 - Software Publishers.

How many employees does BenevolentAI have currently?

Minus sign iconPlus sign icon
As of October 2026, BenevolentAI has approximately 70 employees across 5 continents, including Europe, North America and Africa. Key team members include Chief Executive Officer: B. S., Chief Business Officer (formerly Coo), Co-Founder: I. G. and Chief Financial Officer: J. H. Explore BenevolentAI's employee directory with LeadIQ.

What industry does BenevolentAI belong to?

Minus sign iconPlus sign icon
BenevolentAI operates in the Software Development industry.

What technology does BenevolentAI use?

Minus sign iconPlus sign icon
BenevolentAI's tech stack includes Grafana, Power BI, Apache Airflow, NetSuite, Google Workspace, Okta, Asana and Juniper Networks.

What is BenevolentAI's email format?

Minus sign iconPlus sign icon
BenevolentAI's email format typically follows the pattern of First.Last@benevolent.com. Find more BenevolentAI email formats with LeadIQ.

How much funding has BenevolentAI raised to date?

Minus sign iconPlus sign icon
As of October 2026, BenevolentAI has raised $292M in funding. The last funding round occurred on Sep 17, 2019 for $90M.

When was BenevolentAI founded?

Minus sign iconPlus sign icon
BenevolentAI was founded in 2013.
BenevolentAI logo

BenevolentAI

Software DevelopmentEngland, United Kingdom51-200 Employees

BenevolentAI applies artificial intelligence to biomedicine to help systems read, reason about, and explain vast biomedical knowledge. Its aim is to augment scientists rather than substitute them, a point illustrated when its AI helped identify baricitinib as a potential Covid-19 treatment within 48 hours. The company offers Qor, a strategic decision intelligence platform designed for biotech leaders to harness AI-driven insights across the life sciences landscape.

Headquartered in London, England, BenevolentAI was founded in 2013 and operates as a mid-sized software developer in the life sciences space. Its focus serves biotech and pharmaceutical organizations seeking faster, more informed drug discovery and decision making through AI-enabled interpretation of biomedical knowledge. In early 2024, the company appointed Dr. Joerg Moeller as chief executive officer and executive board member.

Section iconCompany Overview

Stock Symbol
BAI.AS
NAICS Code
5112 - Software Publishers
Founded
2013
Employees
51-200

Section iconFunding & Financials

  • $292M

    BenevolentAI has raised a total of $292M of funding over 3 rounds. Their latest funding round was raised on Sep 17, 2019 in the amount of $90M as a Private Equity.

  • $10M - $25M

    BenevolentAI's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.